Biological
Elasomeran/Davesomeran clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 3
- first study started
- 2020
How studies write it
Studies that test it under each name
Name
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 1
ModernaTX, Inc. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
2019-nCoV Vaccine mRNA-1273 (3) · Ad26COVS1 (1) · BNT162 Vaccine (1) · mRNA-1273.214 COVID-19 vaccine (1)
Studies
Open first, then newest update. How each study uses Elasomeran/Davesomeran is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19CompletedPhase 3ModernaTX, Inc.NCT05815498Written as mRNA-1273.222
- A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19CompletedPhase 2/3ModernaTX, Inc.NCT04649151Written as mRNA-1273.222
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA VaccinesCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT04889209Written as mRNA-1273.222
- A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) VariantsCompletedPhase 2/3ModernaTX, Inc.NCT04927065Written as mRNA-1273.222